Loomis, Sayles & Company’s Aimmune Therapeutics AIMT Stock Holding History

Loomis, Sayles & Company’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-974,719	Closed	-$32.6M	–	812
2019 Q4	$32.6M	Sell	974,719 -3,208	-0.3%	-$89.7K	0.06%	137
2019 Q3	$20.5M	Buy	977,927 +240,301	+33%	+$4.91M	0.04%	205
2019 Q2	$15.4M	Buy	737,626 +170,692	+30%	+$3.51M	0.03%	256
2019 Q1	$12.7M	Sell	566,934 -30,525	-5%	-$719K	0.02%	305
2018 Q4	$14.3M	Buy	597,459 +115,263	+24%	+$2.98M	0.03%	231
2018 Q3	$13.2M	Sell	482,196 -5,076	-1%	-$144K	0.03%	316
2018 Q2	$13.1M	Buy	487,272 +33,952	+7%	+$1.04M	0.03%	352
2018 Q1	$14.4M	Buy	+453,320	New	+$16M	0.03%	333

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Loomis, Sayles & Company's AIMT Position: Q1 2020 in Review

Loomis, Sayles & Company sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 974,719 shares — an estimated $32.6M sold.

Loomis, Sayles & Company first reported a position in AIMT in Q1 2018 and held it in 8 quarters. The position peaked at $32.6M in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

Loomis, Sayles & Company reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Loomis, Sayles & Company sold 974,719 Aimmune Therapeutics shares in Q1 2020, an estimated $32.6M.
Loomis, Sayles & Company first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 8 quarters.
Loomis, Sayles & Company's Aimmune Therapeutics position peaked at $32.6M in Q4 2019.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Loomis, Sayles & Company's 13F filing for Q1 2020, filed 15 May 2020.